Scientists are expressing great confidence in this vaccine, Japanese scientists said that their vaccine has been effective on SARS-COV-2.
Japanese scientists make DNA-based COVID-19 vaccine, third phase trial in America
There is a worldwide competition to make the coronavirus covid-19 vaccine (covid-19 vaccine), but even after 10 months of the virus has passed, no effective vaccine has been given to the scientific world yet. Could. In this effort, scientists of Osaka University, Japan, have now also put forward their claim. Researchers at Osaka University have used two methods of pseudovirus assay and binding assay in their studies. However, this study is still in its early stages. Scientific reports published in this study published in Biorexiv on 21 October have not been reviewed, so the study at Osaka University cannot be considered conclusive as valid data.
DNA-induced vaccine against covid-19
Japanese researchers have developed a DNA-based vaccine that targets the glycoprotein present on the spike of SARS-COV-2 (SARS-COV-2), another member of the same family of the coronavirus covid-19. The SARS virus uses this protein to bind to the ACE-2 receptor in human cells. The virus uses ACE-2 as a tool to enter healthy human cells (HUMAN CELL) and infect the body. Researchers used in-silico gene optimization to develop a highly-optimized DNA sequence (RNA) encoding the spike glycoprotein of the virus. This adaptation algorithm enhances expression and immunogenicity or the body’s immune response. DNA sequence encoding injected into the plasmid of the DNA vaccine pVAX1 (pVAX1). Similarly, they used pseudovirus neutralization assays to assess immune responses. This vaccine is currently in the initial phase of clinical trials in Japan. But preliminary data showed that the vaccine did not cause any adverse effects.
The third phase will be tested in America
On October 22, the US health secretary and scientist Hilda Bastian tweeted on Twitter, with the possibility that the third phase of the DNA vaccine being developed by the University of Osaka might be tested in the US. In the tweet, he also included the announcement of Angis, Osaka University’s partner company in developing the COVID-19 vaccine. It added that a deal was signed to cooperate with American company Brickell Biotech Inc. in preparation for the third phase. Once the first and second stages of the vaccine are successful, they will try to choose the United States for the third phase of testing. Angis has speculated that the Japanese vaccine may hit the market by 2021.